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Platelet-activating factor (PAF), added to the bathing solution, stimulated the cardiac muscarinic K’ channel (KACh) in the cell-attached patch (no 
agonist in the pipette). The PAF-induced K nch channel activation was blocked by WEB2086. a PAF-receptor inhibitor. indicating that the 
PAF-receptor mediated the response. PAF-induced activation was prevented by nordihydroguaieretic acid. a lipoxygenase inhibitor, and AA-861, 
a Mipoxygunase inhibitor, but was not affected by indomethacin. a cycle-oxygenase inhibitor. The PAF-induced K ,,ch channel activity disappeared 
upon formation of inside-out patch. In this inside-out patch, intracellular GTP alone induced maximal channel reactivation, which was inhibited 
by GDP-/%. These results suggest hat S-lipoxygenase metabolites of PAF-released arachidonic acid cause a persistent stimulation of GK but not 
the I&, channel itself, resulting in a receptor-independent activation of the K,,Ch channel by GTP. 
Platelet-activating factor: Arachidonic acid: Lipoxygenase: Cardiac cell: Potassium channel; GTP-binding protein 
1. INTRODUCTION 2. MATERIALS AtiD METHODS 
5-Lipoxygenase metabolites of arachidonic acid stim- 
ulate the G protein-gated muscarinic K’ channel (K,& 
in atria1 myocytes [I]. Since arachidonic acid is released 
into iiiti cell in response to chemical and physical 
stimulation [2,3]. arachidonic acid metabolites are pos- 
sibly common intracellular second messengers to the 
K ACh channel in a variety of physiological and patho- 
physiological regulations of cardiac excitation. Platelet- 
activating factor (PAF) is a phospholipid involved in 
the pathogenesis of various inflammatory diseases and 
in the lethality of anaphyiactic shock [4,5]. Since it is 
known that PAF releases arachidonic acid in various 
tissues [4.5], we hypothesized that PAF may activate the 
K ACh channel via the lipoxygenase pathway of arachi- 
donic acid. We found that PAF! activated the I&, 
channel which is blocked by 5-lipooxygenase inhibitors. 
The PAF-induced activation of the channel clearly 
depended on intracellular GTP, suggesting that the 
target of the arachidonic acid metabolites is GK and not 
the channel itself. Lipoxygenase metabolite-induced/re- 
ceptor-independent stimulation of GK-like proteins 
(Gi,,) may underlie PAF-induced cardiac dysfunction 
bl. 
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Single atrial cells were isolated from guinea-pig heart by enzymatic 
dissociation as described previously [7]. All experiments were per- 
formed at 32-36°C. The patch clamp technique was nsed in the cell- 
attached and inside-out patch configurations. The pipette solution 
contained (in mM): KCI 145. CaCI,, I, MI@,. I, HEPES-KOH buffer 
5 (pH 7.4). atropine 0.01, and theophylline 0. I. The pipette solution 
contained high K+ to increase the single channel conductance of the 
K ,,=,, channel. The bathing solution was (in mM): NaCl 136.5. KCI 
5.4. CaCI, 1.8, MgCI, 0.53, glucose 5.5. HEPES-NaOH buffer 5 (pH 
7.4). The internal solution was (in mM) KCI 140. MgCI: 0.5, EGTA 
5, HEPES-KOH 5 (pH 7.3). PAF. lyso PAF and pertussis toxin (PTX) 
were purchased from Funakoshi Chemicals (Tokyo. Japan). PAF and 
lyso-PAF were dissolved in the bathing solution containingo. 1% BSA. 
Indomethacin, nordihydroguaiaretic acid (NDGA). baicalcin. neomy- 
cin. 4.bromophenacyl bromide (4.BB) and GTP were purchased from 
Sigma (St. Louis, MO). GTP-yS and GDP-DS were from Boehringer 
Mannheim (Germany). WEB2086 and AA-861 were gifts from Boeh- 
,ringer Ingelheim (Germany) and Takeda Ltd. (Osaka. Japan), respec- 
tively. Concentrated stock solutions of inhibitors in ethanol were pre- 
pared fresh each day and kept at 4°C. The final concentration of 
ethanol was less thau 0.5%. which did not affect the PAF-activation 
of the I&, channel. 
3. RESULTS 
Figure 1 shows the currents recorded from a cell- 
attached patch from an atria1 myocyte before and after 
exposure to PAF. Under control conditions. channel 
openings are infrequent in the absence of agonists like 
acetylcholine (ACh) or adenosine in the pipette [7]. 
After addition of PAF (5 &ml) to the bath. channel 
openings increased after a delay (0.5-l min) and 
reached steady levels within 3-5 min (Fig. la). The 
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Fig. 1. Platelet-activating factor (PAF) activation of the muscarinic K’ channel (KhCh). In the cell-attached patch, when PAF applied to the bath 
activated a K’ channel (a). The membrane potential of the patch was held at the resting potential (Er) level. The Er of the cell in this case was 
--80 mV. The locations of the expanded current traces (I .2) are indicated in the upper trace. Current-voltage relation (b) and open-time histogram 
at Er (c) of the PAF-induced K’ channel. The unitary conductance = 46 pS. r, = 0.9 ms. (d) PAF added to the pipette solution did not cause 
activation. The subsequent application of PAF in the bath caused channel activation. (e) The PAF-receptor antagonist, WEB2086 prevented 
PAF-activation of the channel. (f) Lyso PAF did not activate the channel. 
steady state activity of the channel (N-P,) increased 
from 0.0006 (Nap0 of the background activity; N.Pa,bock) 
to 0.1365 in Fig. la. In S experiments, N*P, increased 
to 27.5 + 8.3 times N.Po.bncL (means !I SD) with 0.05 
,ug/ml, 70.3 f: 32.8 with 0.5 pgfrnl and 132.6 + 80.3 with 
5 pglrnl of PAF, respectively. Channel openings 
persisted for more than 10 min after washout of PAP. 
The PAF-activated K’ channel showed strong inward- 
rectification with a conductance of 45-50 pS in 
symmetrical 150 mM K” (Fig 1 b). The open time his- 
togram of the channel could be fitted by a single ex- 
ponential curve with a time constant of -1 ms (Fig. lc). 
These properties identify this channel as the ACh- or 
adenosine-activated KACh channel [7]. 
PAF, added to the pipette solution, did not affect the 
KACh channel (Fig. Id). Subsequent bath-application of 
PAF activated the I&, channel in the same cell-at- 
tached patch without affecting iKI, the other cardiac 
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Fig. 2. The effects of inhibitors of the lipoxygenase and cyclooxygenase pathways (a-d) and the G-I-P-dependence of the PAF-induced channel 
activation (e-g): (a) Indomethacin enhanced the PAF-activation of the K ACh channel. (b,c) NDGA and AA861 blocked activation of the K,,,, 
channel. (d) Baicalein did not affect activation. These inhibitors (indomethacin. NDGA, AA861 and baicalein) suppressed neither the ACW 
adenosineinduced activation of the K ACh channel in the cell-attached patches nor intracellular GTP-l&-induced activation of the channel in the 
inside-out patches at these concentrations. (e) After activation of the K ,,=,, channel by PAF reached a steady level, the patch was excised in the 
internal solution, yielding an ‘inside-out’ patch (arrow). The channel openings disappeared quickly in the inside-out patch but reappeared upon 
application of GTP (0.3 and 1 PM). In the PAF-pretreated patches, GTP (1 PM) almost fully activated the I&, channel. (f-l The GTP-induced 
channel openings in the PAF-pretreated patches were inhibited by GDP-,% (g) Concentration-dependent effect of GTP on the K,,,,, channel in 
the PAF-pretreated (e-e) and untreated (3-o) cell membrane. The symbols and bars are the means + SD obtained from three (PAF-treated) and 
seven (untreated) different patches. The relative N,P, of the K ACl, channel at each concentration of GTP was obtained with reference to the maximum 
channel activity achieved by IO PM GTP-yS in each patch. 
inward-rectifier K’ channel observed in this patch (a inhibitor [ 121. and baicalein (1.5 ,uM). a 12-lipoxygenase 
mean open time of -80 ms at the resting potential which inhibitor [ 131. on PAF-induced channel activation, PAF 
is -80 mV from the K’ equilibrium potential [S]). PAF- could not activate the KACh chpnnel in AA-861-treated 
induced KACh channel activation was antagonized by 10 cells (rr=5), but activated the channel in the baicalein- 
,uM WEB2086, a PAF-receptor antagonist (n=5; Fig. treated cells (w=S). Similar effects of these inhibitors 
le) 191, indicating that PAF-receptor mediated the&-,, were observed in arachidonic acid- and a-adrenergic 
channel activation. Consistent with these results, lyso- activation of the KACi, channel [ 1,141. We conclude, 
PAF. the inactive form of PAF, failed to stimulate the therefore. that the 5-lipoxygenase of arachidonic acid 
K ACh channel in cell-attached patches (n=4. Fig. If). are involved in the PAF-induced activation of the KACh 
Figure 2a-d shows the effects of various inhibitors of channel. 
arachidonic acid metabolism on the PAF-induced acti- 
vation of the KAC,, channel. Indomethacin (10 ,uM), a 
cyclooxygenase inhibitor, failed to affect the PAF-in- 
duced activation of the KAch channel (n=S. Fig. 2a). In 
contrast, NDGA (5 -10 ,uM), the lipoxygenase inhibi- 
tor, prevented the PAF-induced channel activation 
(n=lO, Fig. 2b). Therefore, lipoxygenase but not cyclo- 
oxygenase metabolites of arachidonic acid may be in- 
volved in channel activation. In Fig. 2c and d. we ex- 
amined the effects of AA-861 (3 PM), a 5lipoxygenase 
In Fig. 2e-g, we examined the GTP-dependence of 
the PAF-induced activation of the KACir channel. The 
PAF-induced I&, channel activation observed in cell- 
attached patches disappeared upon formation of inside- 
out patches (Fig. 2e). Neither ACh nor adenosine were 
present in the pipette solution. Yet. upon application of 
low concentrations (0. l-l .O AM) of intracellular GTP. 
channel activity reappeared. Maximal channel activity 
was induced by l-10 AM GTP in these PAF-treated 
patches, which was inhibited by GDP-/% (Fig. 20. Fig- 
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ure 2g shows the relative activity of the KACh channel 
at various concentrations of GTP in both PAF-pretrea- 
ted and untreated inside-out patches. The GTP-induced 
activation of the KACh channel was clearly enhanced by 
pretreatment of the cells with PAF. 
The above observations suggest that the 5-lipoxyge- 
nase metabofites of arachidonic acid released by PAF 
stimulate the basal GDPIGTP exchange of GK in a 
receptor-independent manner. Alternately, these meta- 
bolites may bind to membrane receptors which are cou- 
pled to the K,,, channel. When either PAF or lipoxyge- 
nase metabolites of arachidonic acid, e.g. leukotriene A, 
and Cd, were added to the pipette solution, there was no 
activation of the I&, channel for up to 10 min (Fig. 
Id). This observation rules out the latter hypothesis 
while supporting the former hypothesis. 
To elucidate the coupling between the PAF-receptor 
and arachidonic acid release, we examined the effects of 
PTX, 4-BB (a phospholipase A2 inhibitor) and neomy- 
cin (a phospholipase C inhibitor) on the PAF-induced 
activation of the KACl, channel (Fig. 3a+). In the PTX- 
treated atria1 cells, ACh or adenosine added to the pi- 
pette solution could not activate the KACh channel in the 
cell-attached patches (not shown, see [7]), suggesting 
that PTX ADP-ribosylated GK and uncoupled the m- 
ACh and adenosine receptors from GK in the PTX- 
treated ce!!s [!5,!6]. .As shown in Fig, 3a: PAF added 
to the bath solution also failed to activate the KACh 
channel in cell-attached patches of the PTX-treated 
cells. However, since arachidonic acid, applied to the 
bath. activated the KACl, channel via its lipoxygenase 
metabolites in the cell-attached patches of the PTX- 
treated atria1 cells [l], the PAF-released arachidonic 
acid metabolites themselves probably can stimulate the 
GK uncoupled from mACh and adenosine receptors. 
Therefore, inhibition of the PAF-induced activation of 
the KACI, channel in the PTX-treated cells may indicate 
that PTX prevents the arachidonic acid release induced 
by PA-F in cardiac atria1 cells. Since PTX ADP-ribosy- 
lates and uncouples a certain class of G proteins from 
their receptors [15,16], these results suggest that PTX- 
sensitive G proteins transduce the signals which cause 
arachicionic acid release upon stimulation of PAG-re- 
ceptor in atria1 myocytes. Arachidonic acid can be pro- 
duced from cell membrane phospholipids either by 
phospholipase A, (PLA& or by the sequential actions 
of PLC and diglyceride lipase [2,17]. PAF-activation of 
the KACh channel was prevented by 10 AM 4-BB (Fig. 
3b, n=5) but not by neomycin (100-300 PM, n=5). 
These results suggest hat PLA, is involved in the PAF- 
induced release of arachidonic acid in cardiac atria1 
myocytes. 
4. DISCUSSION 
The present study indicates that the regulatory mech- 
anisms for the GK-KACI, channel system by arachidonic 
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Fig. 3. Signalling from PAF-receptor to arachidonic acid release. (a) 
PAF could not activate the I&, channel in the PTX-treated atrial 
cells. The cells were preincubated in a bathing solution containing 
PTX (500 @ml) for G h at 37°C. (b) 4-BB prevented the PAF- 
induction of the KACh channel activation. (c) Neomycin did not affect 
the PAF-induced channel activation. (d) The proposed signalling 
pathway underlying the PAF-induced activation of the KAch channel 
in cardiac atrial myocytcs. The asterisks indicate the 5lipoxygenase 
substances which activated the KhCh channel in the former study 
VI. 
acid metabolites play an important role in the action of 
PAF on cardiac cells [l ,lO,l I]. Based on the present 
results, the molecular mechanisms underlying PAF-ac- 
tivation of K,,, chaat:ai may be summarized as shown 
in Fig. 3d: PAF binds to the PAF-receptor, which is 
linked with PLA, via PTX-sensitive G proteins. Activa- 
tion of PLAz causes the release of arachidonic acid. The 
released arachidonic acid is metabolized by S-lipoxyge- 
nase. The 5-lipoxygenase metabolites such as leukotrie- 
nes (LTs) cause long-lasting stimulation of the basal 
turn-over of GK, resulting in openings of the KACh 
channel. Consistent with the present electrophysiologi- 
cal results, Piper and Stewart [l&19] showed that PAF 
increased the production of LTC, in rat and guinea-pig 
hearts. 
Since PAF is produced in ischemic reperfusion and 
Volume 289, number 2 FEES LETTERS September 199 1 
sensitized hearts [20,X] and PAF-receptor-antagonists 
prevent the reperfusion- and anaphylaxis-induced car- 
diac dysfunction and arrhythmia [5,22,23], the arachi- 
donic acid metabolite-induced modulation of the G pro- 
tein could be involved in the pathogenesis of ischemia 
and anaphylaxis-induced cardiac damage. 
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